Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond

Nature Reviews Clinical Oncology volume 19, pages 3–4 (2022)Cite this article

Subjects

Daratumumab is an anti-CD38 monoclonal antibody that has transformed the landscape of treatment both for transplant-eligible and -ineligible patients with newly diagnosed multiple myeloma. Addressing important ongoing questions, such as when to de-escalate therapy, will be an important step forward in delivering patient-centred care for those with newly diagnosed multiple myeloma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Moreau, P. et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol. 22, 1378–1390 (2021).

    Article  Google Scholar 

  2. Facon, T. et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 1582–1596 (2021).

    Article  Google Scholar 

  3. Voorhees, P. M. et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 136, 936–945 (2020).

    Article  CAS  Google Scholar 

  4. Moreau, P. et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 394, 29–38 (2019).

    Article  CAS  Google Scholar 

  5. McCarthy, P. L. et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J. Clin. Oncol. 35, 3279–3289 (2017).

    Article  CAS  Google Scholar 

  6. Balmaceda, N. et al. Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC Cancer 21, 730 (2021).

    Article  Google Scholar 

  7. Durie, B. G. M. et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 10, 53 (2020).

    Article  Google Scholar 

  8. Argyriou, A. A., Iconomou, G. & Kalofonos, H. P. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112, 1593–1599 (2008).

    Article  CAS  Google Scholar 

  9. Johnsrud, A. J. et al. Infectious and immunological sequelae of daratumumab in multiple myeloma. Br. J. Haematol. 185, 187–189 (2019).

    Article  Google Scholar 

  10. Dimopoulos, M. A. et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 393, 253–264 (2019).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors are deeply thankful to two of the most inspirational mentors in the field of multiple myeloma, S. Kumar and V. Rajkumar (Mayo Clinic), who helped us to refine this paper. H.M. is the recipient of a Research Early Career Award from Hamilton Health Sciences Foundation.

Author information

Authors and Affiliations

  1. Hematology and Hematologic Malignancy Department, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA

    Ghulam Rehman Mohyuddin

  2. Department of Oncology, McMaster University, Hamilton, Ontario, Canada

    Hira Mian

Authors
  1. Ghulam Rehman Mohyuddin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hira Mian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ghulam Rehman Mohyuddin.

Ethics declarations

Competing interests

H.M. reports consulting for Amgen, BMS, GSK, Janssen, Sanofi and Takeda. H.M. also reports honoraria from BMS, Sanofi and Janssen. She has also received research funding from Janssen. G.R.M. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mohyuddin, G.R., Mian, H. Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond. Nat Rev Clin Oncol 19, 3–4 (2022). https://doi.org/10.1038/s41571-021-00581-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-021-00581-2

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing